Rare and Orphan Diseases: Choosing a Path to Regulatory Approval and Market Success
About 7,000 rare or orphan diseases exist today – In the U.S. alone, these diseases affect less than 200,000 people. With a small population to work from, there’s typically a lack of market push from industry investment.
- The Orphan Drug Act (ODA) and its Impact
- Drug development challenges
- Clinical operation issues
- Clinical trial outcome hurdles
- Pricing obstacles
- And more
Download the white paper.
Who Should Watch?
Certificate of Attendance
Time: 1 p.m. ET, 12 p.m. CT, 10 a.m. PT
Duration: 1 hour